ReviewFrontiers in psychiatry2026
Mental health consequences of contemporary cannabis use in Europe: potency, patterns of use, and health system context.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more developed pharmacovigilance systems, diagnostic networks, and addiction psychiatry services, and other regions. Compared with other regions, in Central and Eastern Europe cannabis-related psychiatric complications remain systematically underestimated. Methods: We conducted a narrative review of peer-reviewed literature, epidemiological reports and national health data published between 2015 and 2025. Sources included EMCDDA, WHO Europe, national statistical agencies and clinical studies on psychiatric outcomes associated with cannabis use. Findings: Cannabis is the most commonly used illicit psychoactive substance in Europe, with higher prevalence in Western countries but rapid growth across Central and Eastern Europe. The proliferation of high-potency cannabis (>15-25%) is consistently linked to elevated risks of psychosis, anxiety, panic symptoms, derealisation episodes and cannabis use disorder. Western Europe demonstrates better detection of cannabis-related psychiatric presentations, whereas Central and Eastern Europe show a hidden clinical burden driven by stigma, limited screening, inconsistent diagnostic practices and the absence of structured monitoring systems. Health systems vary widely in preparedness, particularly regarding early identification of high-risk use, addiction psychiatry integration and routine collection of psychiatric outcome data. Interpretation: Cannabis use is linked to a growing mental health burden in Europe. Stronger THC products and uneven health systems make this problem worse. In Central and Eastern Europe, many cannabis-related mental health problems are missed or not reported. Better monitoring, clearer diagnostic rules, and coordinated action across Europe are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.